Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New procedure aims to cut repeat brain bleed surgeries

NCT ID NCT07626671

Disease control Sponsor: Charite University, Berlin, Germany Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a minimally invasive procedure called middle meningeal artery embolization (MMAE) for chronic subdural hematoma, a common brain bleed in older adults. The procedure blocks the blood supply to the hematoma membrane to prevent rebleeding. Researchers will follow 100 patients for 4 months to see if it reduces hematoma size, improves function, and lowers the need for repeat surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Middle meningeal artery embolization (minimally invasive procedure to block blood flow to the hematoma membrane)
What this could lead to
If successful, this could establish a standard follow-up and identify which patients benefit most from MMA embolization, reducing the need for repeat surgeries.
What could go wrong
This is a single-center registry with only 100 patients, so results may not apply broadly. The procedure itself carries small risks like bleeding or stroke, and it may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with chronic subdural hematoma presenting to the Department of Neuroradiology, Charité - Universitätsmedizin Berlin who are referred for or deemed eligible for middle meningeal artery embolization (MMAE) as part of routine clinical care.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * CT- or MRI-confirmed chronic subdural hematoma (cSDH) * Planned or completed middle meningeal artery embolization (MMAE), either as primary treatment or as adjunct to surgical evacuation * Age ≥ 18 years * Modified Rankin Scale (mRS) ≤ 3 at baseline * Written informed consent including agreement to structured follow-up (follow-up CT scans and clinical assessments) * Willingness and ability to participate in structured follow-up assessments (telephone and/or in-person interviews) Exclusion Criteria: * Acute subdural hematoma requiring emergency neurosurgical intervention * Missing or incomplete baseline clinical or radiological data * Unavailability for prospective follow-up (e.g., no fixed address, no telephone contact)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic subdural hematomas are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hematoma, Subdural, Chronic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic subdural hematomas

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.